4D Molecular Therapeutics 宣布，其4Front-2临床试验已实现超额招募，预计最终入组患者人数将超过500名。这项关键性试验旨在评估其基因疗法在特定适应症中的疗效与安全性。公司预计，最终的随机化分配步骤将于2026年第三季度完成，这标志着试验进程向前迈出了至关重要的一步。试验的顺利推进与积极的招募数据，为后续的数据分析和潜在监管申报奠定了坚实基础。
4D Molecular Therapeutics 宣布，其4Front-2临床试验已实现超额招募，预计最终入组患者人数将超过500名。这项关键性试验旨在评估其基因疗法在特定适应症中的疗效与安全性。公司预计，最终的随机化分配步骤将于2026年第三季度完成，这标志着试验进程向前迈出了至关重要的一步。试验的顺利推进与积极的招募数据，为后续的数据分析和潜在监管申报奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.